SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/c163655b1e981a04459efec4df75ffdc.pdf

Abstract Title

First Name *

Jonathan

Last Name *

Barratt

Co-author 1

Brad Rovin brad.rovin@osumc.edu Ohio State University Wexner Medical Center Division of Nephrology Columbus

Co-author 2

Edward Murphy edward.murphy@travere.com Travere Therapeutics, Inc. Biostatistics San Diego

Co-author 3

Radko Komers radko.komers@travere.com Travere Therapeutics, Inc. Clinical Development, Nephrology San Diego

Co-author 4

Hernán Trimarchi htrimarchi@hotmail.com British Hospital of Buenos Aires Nephrology Service Buenos Aires

Co-author 5

Vlado Perkovic vlado.perkovic@unsw.edu.au University of New South Wales Sydney Faculty of Medicine & Health Sydney

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15